Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Mira A et al. – Extensive validation on breast cancer data sets showed that the GAB2 signature provides a robust prognostic classifier for breast cancer metastatic relapse, largely independent from existing clinical and genomic indicators and from estrogen receptor status. This work highlights a pivotal role for GAB2 and its transcriptional targets in anchorage–independent growth and breast cancer metastatic progression.

Exclusive Author Commentary
E Medico, 10/26/09

In this work a systematic functional screening led to identification of GAB2 as a strong promoter of anchorage independence. The GAB2-signature, composed of genes regulated by GAB2 overexpression, has passed through three different microarray platforms: the genes have been identified in vitro, in normal breast cells rendered anchorage-independent by GAB2, using Illumina microarrays. Then a prognostic classifier was build from these genes in a two-colour Rosetta/Agilent breast cancer microarray dataset, and finally the classifier was validated on multiple Affymetrix dataset of breast cancer. Clearly this signature is "gene-based" and not "probe-based", and it's the first case that a genomic classifier switches microarray platform without the need of any re-tuning to mantain its robustness. In the past, different basic cellular programs, such as wound-healing, hypoxia response, stromal response etc. have been used to build breast cancer prognostic signatures. This work shows that anchorage independence is at least as important as those processes in tumor biology and progression.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address